122,861 results match your criteria Lung Cancer Small Cell


Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis.

Int Immunopharmacol 2022 Jun 21;110:108955. Epub 2022 Jun 21.

Department of Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China. Electronic address:

Introduction: Influence of concomitant use of gastric acid suppressants (GAS) on survival of non-small cell lung cancer (NSCLC) patients receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors has rarely been comprehensively evaluated. A meta-analysis was performed to systematically evaluate the effect of concomitant GAS in NSCLC patients receiving PD-1/PD-L1inhibitors.

Methods: Relevant observational studies were identified by search of Medline, Embase, and Web of Science databases from inception to May 26, 2022. Read More

View Article and Full-Text PDF

External validation of the eighth edition of the TNM classification for lung cancer in small cell lung cancer.

Lung Cancer 2022 Mar 23;170:98-104. Epub 2022 Mar 23.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People's Republic of China. Electronic address:

Objectives: The newly released eighth edition of the American Joint Committee on Cancer TNM staging system for lung cancer seeks to improve prognostic accuracy but lacks external validation for small cell lung cancer (SCLC). Moreover, previous studies posed a few questions concerning survival differences for patients with specific site N3 node involvement or single-site metastasis (SSM) in different distant organs. The aim of this study was to validate the eighth edition of the TNM classification for SCLC in an independent multi-institutional cohort from China and answer the questions raised by the previous research. Read More

View Article and Full-Text PDF

Psychological states regarding adjuvant chemotherapy in patients with non-small cell lung cancer.

Cancer Treat Res Commun 2022 Jun 14;32:100591. Epub 2022 Jun 14.

Department of Surgical Oncology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Electronic address:

Background: Understanding the anxieties and emotions of patients with lung cancer before and after radical surgery is crucial in the decision to undergo postoperative adjuvant chemotherapy. However, the psychological states and changes associated with adjuvant chemotherapy during perioperative periods in patients with non-small cell lung cancer (NSCLC) remain unclear.

Patients And Methods: Participants with a self-reported diagnosis of pathological stage II or III NSCLC who underwent complete surgical resection and received information on postoperative adjuvant chemotherapy (n = 101) were sampled from an online panel in Japan from October 9 to November 19, 2020. Read More

View Article and Full-Text PDF

Applying Artificial Neural Networks to Develop a Decision Support Tool for Tis-4N0M0 Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.

JCO Clin Cancer Inform 2022 Jun;6:e2100176

Department of Radiology, Keio University School of Medicine, Tokyo, Japan.

Purpose: Clear evidence indicating whether surgery or stereotactic body radiation therapy (SBRT) is best for non-small-cell lung cancer (NSCLC) is lacking. SBRT has many advantages. We used artificial neural networks (NNs) to predict treatment outcomes for patients with NSCLC receiving SBRT, aiming to aid in decision making. Read More

View Article and Full-Text PDF

Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.

PLoS One 2022 24;17(6):e0264651. Epub 2022 Jun 24.

Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, Florida, United States of America.

Herein we report the use of Chaperonin-Containing TCP-1 (CCT or TRiC) as a marker to detect circulating tumor cells (CTCs) that are shed from tumors during oncogenesis. Most detection methods used in liquid biopsy approaches for enumeration of CTCs from blood, employ epithelial markers like cytokeratin (CK). However, such markers provide little information on the potential of these shed tumor cells, which are normally short-lived, to seed metastatic sites. Read More

View Article and Full-Text PDF

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.

PLoS One 2022 24;17(6):e0270118. Epub 2022 Jun 24.

Shenyang Pharmaceutical University, Shenyang, China.

Objective: The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China.

Methods: A dynamic state transition model was adopted to simulate life time, direct medical costs and QALYs. In the base case scenario, for patients with unresectable, stage Ⅲ non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy, the treatment group would use durvalumab whereas the control group would use BSC. Read More

View Article and Full-Text PDF

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.

Invest New Drugs 2022 Jun 24. Epub 2022 Jun 24.

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.

This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteCE). This retrospective study evaluated patients with relapsed SCLC who were treated with previously AteCE combination therapy followed by amrubicin monotherapy between August 2019 and May 2021. Clinical efficacy and toxicity were analyzed. Read More

View Article and Full-Text PDF

CircDLG1 promotes malignant development of non-small cell lung cancer through regulation of the miR-630/CENPF axis.

Strahlenther Onkol 2022 Jun 24. Epub 2022 Jun 24.

Department of Clinical Oncology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, 110022, Tiexi District, Shenyang, Liaoning Province, China.

Background: Circular RNAs (circRNAs) have been reported to be crucial modulatory molecules in the etiology of non-small cell lung cancer (NSCLC). This study aimed to probe the precise role and mechanism of circRNA discs large MAGUK scaffold protein 1 (circDLG1) in the malignant progression of NSCLC.

Methods: The abundances of circDLG1, miR-630, and centromere protein F (CENPF) mRNAs were gauged by quantitative real-time polymerase chain reaction (qRT-PCR). Read More

View Article and Full-Text PDF

Intraoperative conversion from video-assisted thoracoscopic lobectomy to thoracotomy for non-small cell lung cancer: does it have an impact on long-term survival?

Interact Cardiovasc Thorac Surg 2022 Jun 24. Epub 2022 Jun 24.

Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether intraoperative conversion to thoracotomy have an impact on long-term survival for patients with non-small cell lung cancer (NSCLC) who underwent video-assisted thoracoscopic lobectomy initially? A total of 461 papers were found using the reported search, of which 6 retrospective cohort studies represented the best evidence to answer the clinical question. The authors, date of publication, journal, country of the authors, patient group, study type, relevant outcomes, and results of these papers are tabulated. Read More

View Article and Full-Text PDF

Inhibition of karyopherin β1-mediated nuclear import disrupts oncogenic lineage- defining transcription factor activity in small cell lung cancer.

Cancer Res 2022 Jun 24. Epub 2022 Jun 24.

The University of Texas Southwestern Medical Center, Dallas, TX, United States.

Genomic studies support the classification of small cell lung cancer (SCLC) into subtypes based on expression of lineage-defining transcription factors ASCL1 and NEUROD1, which together are expressed in ~86% of SCLC. ASCL1 and NEUROD1 activate SCLC oncogene expression, drive distinct transcriptional programs, and maintain the in vitro growth and oncogenic properties of ASCL1 or NEUROD1-expressing SCLC. ASCL1 is also required for tumor formation in SCLC mouse models. Read More

View Article and Full-Text PDF

Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.

Cancer Res 2022 Jun 24. Epub 2022 Jun 24.

Stanford University, Stanford, CA, United States.

Genomic profiling of Bronchoalveolar Lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non-small cell lung cancer (NSCLC) to those detected in matched plasma samples. CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) was used to genotype DNA purified from BAL, plasma and tumor samples from patients with NSCLC. Read More

View Article and Full-Text PDF

Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo.

Drug Deliv 2022 Dec;29(1):1878-1891

Luzhou Key Laboratory of Traditional Chinese Medicine for Chronic Diseases Jointly Built by Sichuan and Chongqing, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, P. R. China.

The main aim of this study was to improve the therapeutic potential of a paclitaxel (PTX) and curcumin (CU) combination regimen using solid lipid nanoparticles (SLNs). PTX and CU were successfully co-encapsulated at a predetermined ratio in SLNs (PC-SLNs) with high encapsulation efficiency (CU: 97.6%, PTX: 95. Read More

View Article and Full-Text PDF
December 2022

Cost-effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China.

J Comp Eff Res 2022 Jun 24. Epub 2022 Jun 24.

College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230000, China.

Crizotinib and ensartinib improved survival in patients with arrangement non-small-cell lung cancer (NSCLC); however, the economic outcomes of using ensartinib versus crizotinib are still unclear. The objective of this study was to assess the cost-effectiveness of ensartinib versus crizotinib for -positive NSCLC patients from the perspective of China's healthcare system. A partitioned survival model with three health states (stable, progressive and death) was developed. Read More

View Article and Full-Text PDF

Targeting molecular alterations in non-small-cell lung cancer: what's next?

Per Med 2022 Jun 24. Epub 2022 Jun 24.

Thoracic Tumors Unit, Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, 08036, Spain.

In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art management of patients with NSCLC (particularly adenocarcinoma or non-adenocarcinoma but with mild tobacco exposure) consists of the determination of , ,  and status, as they have US FDA and EMA approved targeted therapies. The increase in molecular knowledge of NSCLC and the development of drugs against other targets has settled new therapeutic indications. Read More

View Article and Full-Text PDF

PM exposure and risk of lung adenocarcinoma in women of Taiwan: A case-control study with density sampling.

Respirology 2022 Jun 24. Epub 2022 Jun 24.

Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Background And Objective: The prevalence of smoking among women in Taiwan is <5%, but the incidence of lung cancer remains high. This study determined the association between PM (fine particulate matter with an aerodynamic diameter of ≤2.5 μm) exposure and lung cancer among women in Taiwan. Read More

View Article and Full-Text PDF

Overexpression of TRAF4 promotes lung cancer growth and EGFR-dependent phosphorylation of ERK5.

FEBS Open Bio 2022 Jun 23. Epub 2022 Jun 23.

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Tumor necrosis factor receptor-associated factor 4 (TRAF4) is overexpressed in a variety of carcinomas of different origins, but its role in tumorigenesis remains incompletely understood. Previous studies suggest that TRAF4 promotes EGFR activation in non-small cell lung cancer (NSCLC). However, the downstream signaling pathway of TRAF4-mediated EGFR activation, as well as its effects on tumor cells, have not been fully elucidated. Read More

View Article and Full-Text PDF

Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.

Cancer Med 2022 Jun 23. Epub 2022 Jun 23.

Upstate Cancer Center, Upstate Medical University, Syracuse, New York, USA.

Introduction: New treatment strategies for advanced non-small-cell lung carcinoma (NSCLC) include synthetic lethality targets focused on protein arginine methyl transferases such as PRMT5 that exploit the impact of genomic loss of methylthioadenosine phosphorylase (MTAP).

Methods: Twenty nine thousand three hundred seventy nine advanced NSCLC cases underwent hybrid-capture based comprehensive genomic profiling between June 1, 2018 and May 31, 2020. PD-L1 expression was determined by immunohistochemistry (Dako 22C3 PharmDx assay). Read More

View Article and Full-Text PDF

The role of the LINC01234/miR-433-3p/GRB2 ceRNA network in NSCLC cell malignant proliferation.

Comb Chem High Throughput Screen 2022 Jun 24. Epub 2022 Jun 24.

Department of Cardiothoracic Surgery , Jinling Hospital, zhongshan road 305, China.

Background: Non-small cell lung cancer (NSCLC) is associated with high morbidity and mortality. Dysregulation of lncRNAs leads to NSCLC progression.

Objective: This study aims to explore the regulatory mechanism of lncRNA LINC01234 in NSCLC. Read More

View Article and Full-Text PDF

[Clinical Progress in the Immunotherapy of Small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi 2022 Jun;25(6):425-433

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences 
and Peking Union Medical College, Beijing 100730, China.

Small cell lung cancer is a kind of malignant tumor with strong invasiveness and poor prognosis, and the classic therapeutic modality of the disease remains multidisciplinary and comprehensive treatment. Treatment options for small cell lung cancer have been stalled for a long time, and new opportunities have emerged in recent years due to the development and initial experience of immunotherapeutic drugs. Clinical trials of some selected immune checkpoint inhibitors have confirmed the efficacy and safety in small cell lung cancer. Read More

View Article and Full-Text PDF

Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.

Zhongguo Fei Ai Za Zhi 2022 Jun;25(6):409-419

Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, 
West China Hospital, Sichuan University, Chengdu 610041, China.

Background: The incidence of symptomatic radiation pneumonitis (RP) and its relationship with dose-volume histogram (DVH) parameters in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and concurrent once-daily thoracic radiotherapy (TRT) remain unclear. We aim to analyze the values of clinical factors and dose-volume histogram (DVH) parameters to predict the risk for symptomatic RP in these patients.

Methods: Between 2011 and 2019, we retrospectively analyzed and identified 85 patients who had received EGFR-TKIs and once-daily TRT simultaneously (EGFR-TKIs group) and 129 patients who had received concurrent chemoradiotherapy (CCRT group). Read More

View Article and Full-Text PDF

[Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].

Zhongguo Fei Ai Za Zhi 2022 Jun;25(6):401-408

Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, 
Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.

Background: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in pivotal clinical trial studies. We aimed to describe the efficacy and safety of immunotherapy for elderly patients in the "real-world". Read More

View Article and Full-Text PDF

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC.

Front Oncol 2022 7;12:805538. Epub 2022 Jun 7.

Department of Thoracic Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

EGFR-TKI is widely used for EGFR-mutant NSCLC patients. Bleeding is reported as a neglected adverse effect induced by EGFR-TKI. Female patients with lung adenocarcinoma have a high frequency of EGFR mutations. Read More

View Article and Full-Text PDF

Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.

Mol Clin Oncol 2022 Jul 1;17(1):120. Epub 2022 Jun 1.

Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.

Aseptic meningitis is a rare immune-related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non-specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non-small cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.

EClinicalMedicine 2022 Jul 27;49:101430. Epub 2022 May 27.

Department of Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.

Background: PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT-112 also associates with bone (osteotropism), likely driven by its pyrophosphate moiety. This is the first-in-human study of PT-112 monotherapy, exploring its safety and efficacy in a patient population where standard of care therapies were exhausted and novel treatment options are needed. Read More

View Article and Full-Text PDF

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.

Ther Adv Med Oncol 2022 16;14:17588359221105024. Epub 2022 Jun 16.

Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.

Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) chemotherapy in patients with advanced NSCLC and PD-L1 ⩾50%. A systematic literature review and network meta-analysis (NMA) was conducted to identify/compare the efficacy/safety of cemiplimab pembrolizumab or other immune-oncology monotherapies from randomized-controlled trials (RCTs) published in November 2010-2020. Read More

View Article and Full-Text PDF

Combination of [Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.

Pharmaceutics 2022 Jun 16;14(6). Epub 2022 Jun 16.

Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.

Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (Lu)-based probe linked to the somatostatin analog octreotate ([Lu]Lu-DOTA-TATE) is approved for the treatment of certain SSTR-expressing tumors and has been shown to improve survival. However, a limiting factor of PRRT is the potential toxicity derived from the high doses needed to kill the tumor. Read More

View Article and Full-Text PDF

Biodegradable Carbonate Apatite Nanoparticle as a Delivery System to Promote Afatinib Delivery for Non-Small Cell Lung Cancer Treatment.

Pharmaceutics 2022 Jun 10;14(6). Epub 2022 Jun 10.

Integrated Chemical BioPhysics Research, Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.

Nanomedicine-based drug-delivery systems have significant interest in cancer treatment, such as improving the stabilities and biocompatibilities, precise targeting, and reducing toxicities for non-cancerous cells. Herein, this study presents the synthesis and characterisation of carbonate apatite nanoparticles (nCA) and encapsulated afatinib (AFA) as promising drug delivery candidates for lung cancer treatment. nCA/AFA was synthesised and physicochemically characterised, then the encapsulation capacity, drug loading, and cumulative drug release profile were evaluated. Read More

View Article and Full-Text PDF

Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts.

Pharmaceutics 2022 May 28;14(6). Epub 2022 May 28.

College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.

The epidermal growth factor receptor (EGFR) is highly expressed in many non-small cell lung cancers (NSCLC), necessitating the use of EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatments. Osimertinib (OSM), a third-generation TKI, is routinely used in clinics, but T790M mutations in exon 20 of the EGFR receptor lead to resistance against OSM, necessitating the development of more effective therapeutics. Telmisartan (TLM), OSM, and cell cycle and apoptosis regulatory protein 1 (CARP-1) functional mimetic treatments (CFM4. Read More

View Article and Full-Text PDF

Choline Kinase α Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells.

Pharmaceutics 2022 May 27;14(6). Epub 2022 May 27.

Instituto de Investigaciones Biomédicas, CSIC/UAM, 28029 Madrid, Spain.

Lung cancer is one of the main causes of death in developed countries, and non-small cell lung cancer (NSCLC) is the most frequent type (80% of patients). In advanced NSCLC, platinum-based chemotherapy is the frontline palliative treatment, but less than 5% of patients achieve prolonged survival. Immunotherapy has recently been proposed as the standard of care (SoC) as either monotherapy or in combination with chemotherapy for advanced NSCLC. Read More

View Article and Full-Text PDF